Publications by authors named "R Peter Dillon"

Claim this Profile
E
Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients.
Matteo Molica, Gema Miralles, Richard Dillon, Mario Annunziata, Faisal Basheer

Am J Hematol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party.
Jacqueline Cloos, Peter J M Valk, Christian Thiede, Konstanze Döhner, Gail J Roboz, Richard James Dillon

Blood· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measurable residual disease-guided interventions in patients with acute myeloid leukaemia undergoing allogeneic haematopoietic cell transplantation: best practice recommendations from the European Society for Blood and Marrow Transplantation Practice Harmonisation and Guidelines Committee.
Jaime Sanz, Gesine Bug, Fabio Ciceri, Charles Craddock, Richard Dillon

Lancet Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18.
Steven Knapper, Laura W Dillon, Malavika Babu, Abin Thomas, Ian Thomas, Richard James Dillon

Blood· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Systematic Literature Review of Real-World Treatment Effectiveness and Economic and Humanistic Burden in Patients With Muscle-Invasive Bladder Cancer Who Underwent Radical Cystectomy.
Vanessa Shih, Lei Yin, Eleni Theodorou, Ryan Dillon, Sam J Brancato

Clinicoecon Outcomes Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis